CD20×CD3 bispecific antibody achieved significant efficacy in patients with large B-cell lymphoma relapsing after or refractory to CAR-T therapy: a systematic review and meta-analysis
Systematic review demonstrates high overall response rate and complete response in patients with R/R LBCL, suggesting bispecific antibodies may improve outcomes post CAR-T treatment.
Key Points
CD20×CD3 bispecific antibodies significantly improve overall response rates in patients with relapsed or refractory lymphoma, indicating therapeutic promise.
The pooled overall response rate for bispecific antibodies was 54.5%, with a notable complete response rate of 35.6% across multiple trials assessing treatment efficacy.
Observational analysis across nine trials involving 350 participants showed substantial variations in treatment outcomes based on specific bispecific antibody combinations.
Further clinical trials and longer follow-ups are essential to determine the best treatment sequence of bispecific antibodies and CAR-T therapy for these patients.